Park West Asset Management LLC Has $22.86 Million Position in Phreesia, Inc. $PHR

Key Points

• Park West Asset Management LLC increased its stake in Phreesia, Inc. by 111.2%, now holding 894,501 shares valued at approximately $22.9 million, making it the company's 23rd biggest holding.
• Phreesia reported $0.01 earnings per share (EPS) for the recent quarter, exceeding estimates, and has 14.9% year-over-year revenue growth.
• Multiple research firms have upgraded their price targets for Phreesia, with Canaccord Genuity setting a target of $38.00 and 93% of analysts rating the stock as a "Buy."

Park West Asset Management LLC lifted its holdings in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 111.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 894,501 shares of the company's stock after acquiring an additional 470,931 shares during the quarter. Phreesia makes up about 1.8% of Park West Asset Management LLC's portfolio, making the stock its 23rd biggest holding. Park West Asset Management LLC owned 1.52% of Phreesia worth $22,863,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. KBC Group NV acquired a new stake in Phreesia during the 1st quarter valued at $74,000. CWM LLC raised its position in shares of Phreesia by 994.9% in the first quarter. CWM LLC now owns 4,040 shares of the company's stock valued at $103,000 after purchasing an additional 3,671 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Phreesia by 53.0% during the 1st quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company's stock worth $137,000 after buying an additional 1,825 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Phreesia by 10,605.7% during the first quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock worth $145,000 after acquiring an additional 5,621 shares during the period. Finally, BNP Paribas Financial Markets acquired a new position in Phreesia in the 4th quarter valued at $163,000. 92.10% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PHR has been the topic of a number of analyst reports. Mizuho initiated coverage on shares of Phreesia in a research report on Wednesday, August 27th. They set an "outperform" rating and a $36.00 target price on the stock. JMP Securities boosted their price target on Phreesia from $30.00 to $34.00 and gave the company a "market outperform" rating in a research note on Monday. Stephens restated an "overweight" rating and set a $32.00 price objective on shares of Phreesia in a research note on Wednesday, September 3rd. KeyCorp lifted their price objective on Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a report on Monday, July 14th. Finally, Raymond James Financial set a $33.00 target price on Phreesia and gave the stock an "outperform" rating in a report on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating and twelve have given a Buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $34.08.

Phreesia Stock Performance

Shares of PHR stock traded down $1.21 on Wednesday, reaching $25.34. The company had a trading volume of 1,310,199 shares, compared to its average volume of 1,006,832. The business's 50-day moving average is $28.27 and its 200 day moving average is $26.50. Phreesia, Inc. has a one year low of $17.07 and a one year high of $32.76. The company has a quick ratio of 1.95, a current ratio of 2.12 and a debt-to-equity ratio of 0.02.

Phreesia (NYSE:PHR - Get Free Report) last released its quarterly earnings data on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.08. The business had revenue of $117.26 million during the quarter, compared to analysts' expectations of $116.39 million. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%. The firm's quarterly revenue was up 14.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.03) EPS. Phreesia has set its FY 2026 guidance at EPS. Equities analysts predict that Phreesia, Inc. will post -1.1 EPS for the current year.

Insider Buying and Selling at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 1,245 shares of the business's stock in a transaction that occurred on Thursday, July 17th. The shares were sold at an average price of $26.89, for a total transaction of $33,478.05. Following the sale, the general counsel directly owned 136,978 shares of the company's stock, valued at $3,683,338.42. The trade was a 0.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David Linetsky sold 17,445 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $29.73, for a total transaction of $518,639.85. Following the completion of the sale, the insider directly owned 174,002 shares in the company, valued at approximately $5,173,079.46. This represents a 9.11% decrease in their position. The disclosure for this sale can be found here. Insiders sold 109,292 shares of company stock worth $3,295,323 over the last quarter. Insiders own 5.50% of the company's stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.